Whole genome amplicon sequencing and phylogenetic analysis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from lineage B.1.36.27 isolated in Hong Kong. (2nd January 2022)

• Record Type: Journal Article
• Authors: Tsang, Hin Fung; Yu, Allen Chi Shing; Wong, Heong Ting; Leung, Wai Ming Stanley; Chiou, Jiachi; Wong, Yin Kwan Evelyn; Yim, Aldrin Kay Yuen; Tsang, Dominic Ngai Chong; Tsang, Alan KL; Wong, Wing Tak; Wong, Sze Chuen Cesar; Cho, William Chi Shing
• Is Part Of: Expert review of molecular diagnostics. Volume 22:Number 1(2022)
• Page Start: 119
• Page End: 124
• Publication Date: 2022-01-02
• Subjects: COVID-19 -- SARS-CoV-2 -- whole genome sequencing -- NGS -- phylogenetic analysis -- B.1.36.27 -- viral genome; Molecular diagnosis -- Periodicals; 616.0758205
• DOI: 10.1080/14737159.2022.2015330
• Languages: English
• ISSNs: 1473-7159

Abstract

ABSTRACT: Background: The import of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) lineage B.1.36.27 has sparked the fourth wave of COVID-19 outbreak in Hong Kong. This strain has been circulating in Hong Kong since September 2020 but rarely found in other countries (<1%). Research design and Methods: A total of 14 SARS-CoV-2 genome sequences collected from patients in Hong Kong between July 2020 and March 2021 were determined by whole viral genome sequencing using Illumina next-generation sequencing platform, followed by phylogenetic analysis. Results: Of the 14 SARS-CoV-2 genome sequences analyzed, 9 strains belonged to the PANGO lineage B.1.36.27, GISAID clade GH, and Nextclade clade 20A. Compared to the reference genome, 31 nucleotide differences and 11 amino acid differences were identified in the genome of the SARS-CoV-2 from PANGO lineage B.1.36.27. Conclusions: We reported the nucleotides and amino acids mutations identified in the SARS-CoV-2 from PANGO lineage B.1.36.27. Our viral genome sequences enriched the understanding of SARS-CoV-2 mutational landscape and improved the repertoire of known SARS-CoV-2 variants for tracking and tracing. From this study, we found no evidence to show that SARS-CoV-2 from lineage B.1.36.27 can compromise existing vaccines and antibody therapies.